Andrew S Huhn1, Kelly E Dunn2. 1. Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, MD, United States. 2. Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: kdunn9@jhmi.edu.
Abstract
BACKGROUND & OBJECTIVE: Buprenorphine is an underutilized pharmacotherapy that can play a key role in combating the opioid epidemic. Individuals with opioid use disorder (OUD) often struggle to find physicians that prescribe buprenorphine. Many physicians do not have the waiver to prescribe buprenorphine, and a large proportion of physicians that are waivered do not prescribe to capacity. This study aimed to quantitatively understand why physicians do not utilize buprenorphine for the treatment of OUD more frequently. METHODS: Physicians (n=558) with and without the waiver to prescribe buprenorphine were surveyed about perceived drawbacks associated with prescribing buprenorphine. Furthermore, resources were identified that would encourage those without the waiver to obtain it, and those with the waiver to accept more new patients. The survey was distributed online to physicians in the spring/summer of 2016 via the American Society for Addiction Medicine and American Medical Association listservs. RESULTS AND CONCLUSIONS: A logistic regression analysis was used to identify reasons that respondents indicated no willingness to increase prescribing (χ2(4)=73.18, p<0.001); main reasons were lack of belief in agonist treatment (OR 3.98, 95% CI, 1.43 to 11.1, p=0.008), lack of time for additional patients (OR 5.54, 95% CI, 3.5 to 8.7, p<0.001), and belief that reimbursement rates are insufficient (OR 2.50, 95% CI, 1.3 to 4.8, p=0.006). Differences between non-waivered and waivered physicians concerning attitudes toward buprenorphine treatment as well as resources that would increase willingness to prescribe are also discussed. Identifying barriers to buprenorphine utilization is crucial in expanding treatment options for individuals with OUD.
BACKGROUND & OBJECTIVE:Buprenorphine is an underutilized pharmacotherapy that can play a key role in combating the opioid epidemic. Individuals with opioid use disorder (OUD) often struggle to find physicians that prescribe buprenorphine. Many physicians do not have the waiver to prescribe buprenorphine, and a large proportion of physicians that are waivered do not prescribe to capacity. This study aimed to quantitatively understand why physicians do not utilize buprenorphine for the treatment of OUD more frequently. METHODS: Physicians (n=558) with and without the waiver to prescribe buprenorphine were surveyed about perceived drawbacks associated with prescribing buprenorphine. Furthermore, resources were identified that would encourage those without the waiver to obtain it, and those with the waiver to accept more new patients. The survey was distributed online to physicians in the spring/summer of 2016 via the American Society for Addiction Medicine and American Medical Association listservs. RESULTS AND CONCLUSIONS: A logistic regression analysis was used to identify reasons that respondents indicated no willingness to increase prescribing (χ2(4)=73.18, p<0.001); main reasons were lack of belief in agonist treatment (OR 3.98, 95% CI, 1.43 to 11.1, p=0.008), lack of time for additional patients (OR 5.54, 95% CI, 3.5 to 8.7, p<0.001), and belief that reimbursement rates are insufficient (OR 2.50, 95% CI, 1.3 to 4.8, p=0.006). Differences between non-waivered and waivered physicians concerning attitudes toward buprenorphine treatment as well as resources that would increase willingness to prescribe are also discussed. Identifying barriers to buprenorphine utilization is crucial in expanding treatment options for individuals with OUD.
Authors: Bradley D Stein; Rosalie Liccardo Pacula; Adam J Gordon; Rachel M Burns; Douglas L Leslie; Mark J Sorbero; Sebastian Bauhoff; Todd W Mandell; Andrew W Dick Journal: Milbank Q Date: 2015-09 Impact factor: 4.911
Authors: Ruth E Dubin; John Flannery; Paul Taenzer; Andrew Smith; Karen Smith; Ralph Fabico; Jane Zhao; Lindsay Cameron; Dana Chmelnitsky; Rob Williams; Leslie Carlin; Hannah Sidrak; Sanjeev Arora; Andrea D Furlan Journal: Stud Health Technol Inform Date: 2015
Authors: Paul J Fudala; T Peter Bridge; Susan Herbert; William O Williford; C Nora Chiang; Karen Jones; Joseph Collins; Dennis Raisch; Paul Casadonte; R Jeffrey Goldsmith; Walter Ling; Usha Malkerneker; Laura McNicholas; John Renner; Susan Stine; Donald Tusel Journal: N Engl J Med Date: 2003-09-04 Impact factor: 91.245
Authors: Andrew S Huhn; J Gregory Hobelmann; Justin C Strickland; George A Oyler; Cecilia L Bergeria; Annie Umbricht; Kelly E Dunn Journal: JAMA Netw Open Date: 2020-02-05
Authors: Raminta Daniulaityte; Ramzi W Nahhas; Sydney Silverstein; Silvia Martins; Angela Zaragoza; Avery Moeller; Robert G Carlson Journal: Drug Alcohol Depend Date: 2019-09-22 Impact factor: 4.492